AD/PD & AAN Presentations Posted

With the PPMI data set and biospecimen sample inventory rapidly growing, PPMI data is increasingly being presented around the globe.  Below are some highlights of PPMI data presentations from this past season:

American Academy of Neurology (AAN) Annual Meeting, Washington, DC – April 18-25

Assessment of Parkinson disease progression using 123- I I-Ioflupane SPECT: Update from the Parkinson Progression Marker Initiative Trial – Seibyl, J; Jennings, D; Marek, K; The Parkinson’s Progression Markers Initiative investigators

Presence of Cerebral Amyloid Modulates Phenotype & Pattern of Neurodegeneration in Early Parkinson?s Disease – McMillan, C; Wolk, D

CSF A-beta 1-42 predicts cognitive impairment in de novo PD patients – Terrelonge, M; Marder, K; Weintraub, D; Alcalay, R

Objective Measurement of Upper Extremity Motor Function in de novo Parkinson?s Disease – Chahine, L; Uribe, L; Hogarth, P; Jennings, D; The Parkinson?s Progression Markers Initiative

Identifying drug-naïve Parkinsonism with Non-motor features & CSF biomarkers: A case-control study – Jain, S; Young Park, S; Comer, D; Rudoy, D; Ivanco, L

Using non-motor features to define clinical and biomarker patterns of early drug-naïve Parkinsonism – Jain, S; Young Park, S; Comer, D

Non-motor symptoms in early drug-naïve Parkinson?s disease – Liu, R; Umbach, D; Peddada, S; Xu, Z; Tröster, A; Huang, X; Chen, H

International Symposium on Biomedical Imaging, Brooklyn, NY – April 16-19

Early Detection of Parkinson?s Disease Through Shape Based Features From 123I-Ioflupane SPECT Imaging – Bhalchandra, N; Prashanth, R; Roy, S; Noronha, S

AD/PD, Nice, France – March 18-22

Longitudinal PD Biomarker Studies: DeNoPa and PPMI – Mollenhauer, B

Progression of White Matter Degeneration in Early Parkinson?s Disease: A Multicenter Evaluation Using Diffusion Tensor Imaging – Zhang, Y; Wu, K; Schuff, N; The Parkinson’s Progression Markers Initiative